SCHEMBL25365448

SCHEMBL25365448

CC(C)N1CCN(c2ccc(-c3ccc4nc(-c5ccc(S(C)(=O)=O)cc5)n(C5CC5)c4n3)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.43
▸ ALK Q9UM73 4/20 0.41
▸ TNF P01375 1/20 0.41
▸ TRPV4 Q9HBA0 2/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ CLK1 P49759 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ DYRK2 Q92630 1/20 0.39
▸ GPR119 Q8TDV5 3/20 0.38
▸ MAOA P21397 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ OGA O60502 1/20 0.36
▸ SYK P43405 1/20 0.36
▸ PTGS2 P35354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25366146 0.87 HRH3 (0.47) HRH3ALKTNFMAOAMAOB
SCHEMBL30557377 0.87 HRH3 (0.47) HRH3ALKTNFMAOAMAOB
SCHEMBL25367766 0.85 TNF (0.41) TNFPIK3CAMTORCLK1CDK9
SCHEMBL25366373 0.83 TNF (0.39) TNFPIK3CAMTORDYRK1AGPR119
SCHEMBL25364553 0.80 TGFBR1 (0.46) HRH3ALKTNFCLK1CDK9
SCHEMBL30557460 0.80 HRH3 (0.37) HRH3ALKTNFPIK3CAMTOR
SCHEMBL25368100 0.80 HRH3 (0.37) HRH3ALKTNFPIK3CAMTOR
SCHEMBL25367243 0.78 MAP4K1 (0.47) TRPV4GPR119JAK2JAK1TYK2
SCHEMBL30899925 0.78 TRPV4 (0.41) HRH3TRPV4GPR119JAK2JAK1
SCHEMBL30557399 0.78 MAP4K1 (0.47) TRPV4GPR119JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177363-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-06-05 — — US disclosed
EP-4479135-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 Bristol-Myers Squibb Company (US) 2024-12-25 — — EP disclosed
CN-118786130-A Substituted imidazopyridinyl compounds useful as TLR9 inhibitors 百时美施贵宝公司 2024-10-15 — — CN disclosed
WO-2023159154-A9 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-10-10 — — WO disclosed
WO-2023159154-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177363-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 TLR9, TLR3, TLR1 HRH3 180/4885ALK 334/4885TNF 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback